---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-008959"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:50:27.890261+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Citius shareholders elect directors, approve 2023 equity plan, ratify auditor

## Summary
- All seven director nominees elected; Myron Holubiak received 27,833,866 for votes, 1,956,427 withheld; 45,937,200 broker non-votes.
- 2023 Omnibus Stock Incentive Plan approved with 22,065,354 for, 6,944,243 against, 780,696 abstain, 45,937,200 broker non-votes.
- Ratification of Wolf & Company, P.C. as independent auditor for fiscal 2023 passed with 73,110,304 for, 1,546,136 against, 1,071,053 abstain.

## SEC filing metadata
- accession: 0001213900-23-008959
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/0001213900-23-008959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/ea172894-8k_citiuspharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-008959
- JSON: https://secwatch.observer/filing/0001213900-23-008959.json
- Plain text: https://secwatch.observer/filing/0001213900-23-008959.txt

## Key facts
- Shareholder Votes
  Citius Pharmaceuticals, Inc. shareholders approved Approval of the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan at the 2023-02-07 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-02-07
  source text: Next, at the meeting, our stockholders approved the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan. The vote for such approval was 22,065,354 shares for, 6,944,243 shares against, 780,696 shares abstaining, and 45,937,200 broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/0001213900-23-008959-index.htm
- Shareholder Votes
  Citius Pharmaceuticals, Inc. shareholders approved Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year ending September 30, 2023 at the 2023-02-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-02-07
  source text: Finally, at the meeting, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2023. The vote for such approval was 73,110,304 shares for, 1,546,136 shares against, 1,071,053 shares abstaining, and no broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/0001213900-23-008959-index.htm
- Shareholder Votes
  Citius Pharmaceuticals, Inc. shareholders approved Election of seven directors for a one-year term at the 2023-02-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-02-07
  source text: We held our 2023 annual meeting of stockholders on February 7, 2023. At the meeting, stockholders elected the following seven members to our Board of Directors for a one-year term expiring at the annual meeting of stockholders to be held in 2024 and until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Myron Holubiak 27,833,866 1,956,427 45,937,200 Leonard Mazur 27,708,003 2,082,290 45,937,200 Suren Dutia 27,404,373 2,385,920 45,937,200 Carol Webb 27,206,268 2,584,025 45,937,200 Howard Safir 27,493,869 2,296,424 45,937,200 Dr. Eugene Holuka 27,093,439 2,696,854 45,937,200 Dennis M. McGrath 27,486,435 2,303,858 45,937,200
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/0001213900-23-008959-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.